SMARCB1 and sarcoma: Increased BRD9 incorporation into the ncBAF complex has been reported in SMARCB1-mutated sarcoma cell lines [52] and demonstrated to induce synthetic lethality in synovial sarcoma and rhabdomyosarcoma cell lines with perturbed SMARCB1 [44].